HepaGam B FDA Approval History
FDA Approved: Yes (First approved January 30, 2006)
Brand name: HepaGam B
Generic name: hepatitis B immune globulin
Company: Cangene
Treatment for: Exposure to Hepatitis B Virus
HepaGam B is hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus. HepaGam B is indicated for treatment following acute exposure to hepatitis B virus.
Development timeline for HepaGam B
| Date | Article |
|---|---|
| Jan 30, 2006 | Approval HepaGam B - Cangene - Treatment for Exposure to Hepatitis B |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
